


Product Name	: AVL-292
Synonyms	: Spebrutinib; CC-292
Cat No.	: M10735
CAS Number	: 1202757-89-8
Molecular Formula	: C ₂₂ H ₂₂ FN ₅ O ₃
Formula Weight	: 423.44
Chemical Name	: 2-Propenamamide, N-[3-[[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-
Description	: AVL-292 (Spebrutinib, CC-292) is a highly selective, covalent Btk inhibitor with IC ₅₀ of <1 nM; also less potently inhibits Yes, c-Src, Brk, Lyn, and Fyn with IC ₅₀ s of 723 nM, 1.729 uM, 2.43 uM, 4.4 uM, and 7.15 uM, respectively; shows anti-inflammatory activity in the collagen-induced arthritis model of autoimmune disease; also prevents NRG- and EGF-dependent growth factor-driven resistance to lapatinib in HER2(+) breast cancer cells. Rheumatoid Arthritis Phase 2 Clinical.
Pathway	: Tyrosine Kinase
Target	: BTK
Receptor	: BRK; BTK; c-Src; Lyn; Yes
Solubility	: DMSO: ≥ 45 mg/mL
SMILES	: <chem>C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(OCCOC)C=C3)=NC=C2F)=C1)=O</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:



1. Evans EK, et al. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28. || 2. Eda H, et al. Leukemia. 2014 Sep;28(9):1892-901. || 3. Wang X, et al. Mol Cancer Ther. 2016 Sep;15(9):2198-208.